



12-10-01

CASE 4-3087

RECEIVED
TECH CENTER 1600/2900
DEC 11 3 2001
TECH CENTER 1600/2900
DEC 27 2001

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 041585885 US
Express Mail Label Number

December 6, 2001
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

MATTHEWS ET AL.

APPLICATION NO: 09/930,335

FILED: AUGUST 15, 2001

FOR: SPONTANEOUSLY DISPERSIBLE N-BENZOYL STAUROSPORINE
COMPOSITIONS

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report for parent application PCT/EP00/01196. Copies are enclosed herewith.

EP 0 733 358 A2, EP 0 711 556, and DE 44 18 115 A1 are substantially equivalent to U.S. 5,726,164, U.S. 5,658,898, and U.S. 5,932,243. Copies of the U.S. patents are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6926

Date: 12/6/01

Norbert Gruenfeld
Norbert Gruenfeld
Agent for Applicants
Reg. No. 30,061